drugset / Trial / NCT02479802
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5% albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2014-11
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin | Protein / enzyme biologic | 5 % | — |
| Subject | Albumin | Protein / enzyme biologic | 3000 ml | — |